L-type voltage-gated calcium channel (LTCC) and potassium channel (LTCC/K+ channel)

L-type voltage-gated calcium channels (LTCCs) and potassium channels are essential components of the electrical signaling system in excitable tissues, particularly the heart and vascular smooth muscle (StatPearls, NBK482473). LTCCs, such as the Cav1.2 subunit (UniProt Q13936), allow the influx of calcium ions during the action potential, which is vital for muscle contraction and pacemaker activity. Potassium channels, including the hERG and delayed rectifier channels, facilitate the efflux of potassium ions to repolarize the cell membrane (StatPearls, NBK534827). Pharmacological agents that target both channel types, such as bepridil or amiodarone, are typically used to treat complex cardiovascular conditions like refractory angina or specific arrhythmias (PubChem, CID 2351; PubMed, 11579026). By blocking these channels, these drugs can reduce myocardial oxygen demand, decrease heart rate, and alter the cardiac refractory period. However, the dual activity increases the complexity of their safety profile, necessitating monitoring for adverse effects like bradycardia or QT interval prolongation. This multi-target approach is often employed when single-channel blockade is insufficient to control rhythm or ischemic symptoms. Clinical management requires careful consideration of drug-drug interactions and electrolyte balance to mitigate proarrhythmic risks.

Other names

L-type calcium channelPotassium channelVoltage-gated calcium channelVoltage-gated potassium channelLTCCK+ channelVoltage-dependent calcium channelCalcium channel, L-typePotassium channel, voltage-gated

Inhibition of ion conductance through the pore-forming subunits of L-type calcium channels (e.g., Cav1.2) and various voltage-gated potassium channels (e.g., hERG) to modulate the cardiac action potential and vascular tone (StatPearls, NBK482473; StatPearls, NBK534827).